Darbepoetin alfa for the treatment of anemia associated with myelodysplastic syndromes: Efficacy and quality of life

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 1007-1014

  Oliva, Esther N ^a   Nobile, Francesco ^a   Alimena, Giuliana ^b   Specchia, Giorgina ^c   Danova, Marco ^d   Rovati, Bianca ^d   Ronco, Francesca ^a   Impera, Stefana ^e   Risitano, Antonio ^f   Alati, Caterina ^a   Breccia, Massimo ^b   Carmosino, Ida ^b   Vincelli, Iolanda ^a   Latagliata, Roberto ^b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Hematology Division   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Anemia; Apoptosis; Darbepoetin alfa; Hemoglobin; Myelodysplastic syndromes; Quality of life

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; ERYTHROPOIETIN;

ANEMIA; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; STEM CELL; TREATMENT DURATION; TREATMENT RESPONSE; AGED; ANALOGS AND DERIVATIVES; BLOOD TRANSFUSION; COMPLICATION; DOSE RESPONSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 77953527063     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003728610     Document Type: Article

References (28)

1. Catenacci DV, Schiller GJ. Myelodysplasic syndromes: a comprehensive review. Blood Rev 2005;19:301-319.
2. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cell in 50 patients with myelodysplastic syndromes. Blood 1995;86: 268-276.
3. Bouscary D, De Vos J, Guesnu M, et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11:839-845.
4. Mundle S, Venugopal P, Shetty V, et al. The relative extent and propensity of CD34+ vs. CD347 cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 1999;69: 152-159.
5. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-1601.
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
7. Oliva EN, D'Angelo A, Martino B, Nobile F, Dimitrov BD, Perna A. More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol 2002;14:3182-3184.
8. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005;352: 536-538.
9. Italian Cooperative Study Group for rHuEPO in myelodyspastic syndromes. A randomized double-blind placebocontrolled study with subcutaneous recombinant human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol 1998;103:1070-1074.
10. Terpos E, Mougiou A, Kouraklis A, et al.; for The Greek MDS Study Group. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002;118:174-180.
11. Ross SD, Allen IE, Probst CA, Sercus B, Crean SM, Ranganathan G. Efficacy and safety of erythropoiesisstimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007;12: 1264-1273.
12. Park S, Grabar S, Kelaidi C, et al.; for the GFM group (Groupe Francophone des Myé lodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-582.
13. Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic sindrome. Ann Hematol 2005;84:167-176.
14. Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005;128:204-209.
15. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005;16:1921-1927.
16. Mannone L, Gardin C, Quarre MC, et al. Groupe Francais des Myelodysplasies. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome: results of a phase II study. Br J Haematol 2006;133:513-519.
17. Giraldo P, Nomdedeu B, Loscertales J, et al. Aranesp in Myelodysplastic Syndromes (ARM) Study Group. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006;107:2807-2816.
18. Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008;142:379-393.
19. Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S. Erythropoiesis- stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008;87:527-536.
20. Jädersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008;26:3607-3613.
21. Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, et al.; GFM group (Groupe Francophone des Myé lodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008;111:574-582.
22. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009;114: 2393-2400.
23. Cheson BD, Bennett JM, Kantarjian H, et al. World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96: 3671-3674.
24. Chow SC, Shao J, Wang H. Sample size calculations in clinical research. In: Fleiss JL, Levin B, Paik MC, editors. Statistical methods for rates and proportions. 3rd ed. New York: John Wiley & Sons; 2003.
25. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
26. Marsh JCW, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. Semin Hematol 2007;44:138-147.
27. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299: 914-924.
28. US Food and Drug Administration, Center for Drug Evaluation and Research. Information for healthcare professionals. Erythropoiesis stimulating agents (ESP). Online posting 11 August 2007. Available from: http://www.fda.gov/ cder/drug/InfoSheets/HCP/RHE200711HCP.htm